CHRM1 and movement disorder: Accordingly, we tested the effects of a combined drug treatment regimen (D2R agonist + M1R antagonist) in a well-known model of movement disorder, i.e., the reserpinized mouse (Leao et al., 2015; Leal et al., 2016).